<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Schwannomatoses related to genetic variants other than &lt;i&gt;NF2&lt;/i&gt;</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Schwannomatoses related to genetic variants other than <i>NF2</i></h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Schwannomatoses related to genetic variants other than <i>NF2</i></div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kaleb Yohay, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amanda Bergner, MS, CGC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John de Groot, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 19, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13669822"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Schwannomatosis is the name originally coined for a neurocutaneous syndrome that is genetically distinct from neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2). It was first recognized as distinct from NF2 in the late 1990s [<a href="#rid1">1</a>].</p><p>In 2022, the nomenclature for NF2 and schwannomatosis was further updated to recognize the disorders as part of a spectrum of schwannoma predisposition syndromes with extensive clinical overlap, defined in many cases by pathogenic variants in one of several genes on chromosome 22 [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>NF2</em>-related schwannomatosis (shortened to "NF2" in this topic and others for brevity), formerly neurofibromatosis type 2</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>SMARCB1</em>-related schwannomatosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>LZTR1</em>-related schwannomatosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other schwannomatoses, including those related to loss of heterozygosity (LOH) of chromosome 22q</p><p></p><p>This topic will cover the non-<em>NF2</em>-related schwannomatoses, which we will continue to refer to as "schwannomatosis" in this topic for brevity and consistency, unless otherwise noted.</p><p>Schwannomatosis is characterized by a predisposition to form benign nerve sheath tumors called schwannomas, in the absence of intradermal and bilateral vestibular schwannomas. The majority of familial cases are caused by inactivating pathogenic variants in either <em>SMARCB1</em> or <em>LZTR1</em>, tumor suppressor genes on chromosome 22, but these variants are associated with &lt;50 percent of sporadic cases. Most patients present in adulthood with multiple schwannomas and pain, and approximately 20 percent of patients have a family history of schwannomas or schwannomatosis. Treatment is symptomatic, focused primarily on pain management.</p><p>The epidemiology, pathology, clinical manifestation, diagnosis, and treatment of schwannomatosis will be reviewed here. The following related topics are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5206.html" rel="external">"<i>NF2</i>-related schwannomatosis (formerly neurofibromatosis type 2)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15269.html" rel="external">"Peripheral nerve tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5196.html" rel="external">"Intradural nerve sheath tumors"</a>.)</p><p></p><p class="headingAnchor" id="H9166935"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Schwannomatosis is a rare disorder with a prevalence approximately half that of <em>NF2</em>-related schwannomatosis (NF2) [<a href="#rid3">3,4</a>]. In a northwest England population, the prevalence was estimated at 1 in 126,000 [<a href="#rid3">3</a>]. There is no known predilection based on sex, race, or ethnicity.</p><p>Family history is the only known risk factor. The disorder is familial in approximately 20 percent of patients [<a href="#rid4">4-6</a>], although this may be an underestimate, as there may be incomplete penetrance for <em>SMARCB1</em> or <em>LZTR1</em> pathogenic variants. An understanding of the phenotypic spectrum is still evolving.</p><p>Patients with schwannomatosis account for 2 to 10 percent of all individuals undergoing schwannoma resection [<a href="#rid4">4,5,7,8</a>]. In a retrospective surgical series of over 200 schwannoma excisions, for example, 90 percent of patients had solitary (nonsyndromic) tumors, 9 percent met diagnostic criteria for definite or probable schwannomatosis, and 1 percent had NF2 [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H9166943"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Schwannomatosis is a genetic tumor suppressor syndrome that leads to formation of multiple noncutaneous schwannomas on peripheral nerves, spinal roots, and cranial nerves.</p><p class="headingAnchor" id="H1329941549"><span class="h2"><i>SMARCB1 </i>inactivation</span><span class="headingEndMark"> — </span>Inactivating germline pathogenic variants in <em>SMARCB1</em> on chromosome 22 are the most common cause of familial schwannomatosis [<a href="#rid9">9</a>]. <em>SMARCB1</em> pathogenic variants are present in 40 to 50 percent of families with schwannomatosis and up to 10 percent of sporadic cases [<a href="#rid10">10-14</a>].</p><p><em>SMARCB1</em>, previously called <em>INI1</em>, is thought to act as a tumor suppressor gene that affects the expression of genes regulating the cell cycle, growth, and differentiation.</p><p>In schwannomas containing <em>SMARCB1</em> pathogenic variants, additional genetic alterations are almost always present, including loss of one copy of chromosome 22 and inactivating pathogenic variants in NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor (<em>NF2</em>) [<a href="#rid15">15</a>]. Such cases suggest a four-hit, three-step model of tumorigenesis, in which the altered germline <em>SMARCB1</em> gene copy is present in the tumor (hit 1), part or all of chromosome 22 containing the wildtype <em>SMARCB1</em> gene copy and a wildtype copy of the <em>NF2</em> gene is lost (hits 2 and 3), and the remaining wildtype <em>NF2</em> gene copy is altered (hit 4) [<a href="#rid12">12,16</a>].</p><p>Some loss-of-function germline pathogenic variants in <em>SMARCB1 </em>can cause an inherited predisposition to rhabdoid tumors that occur in childhood, including malignant rhabdoid tumors of the kidney, atypical teratoid/rhabdoid tumors (ATRT) of the central nervous system, and extrarenal rhabdoid tumors [<a href="#rid9">9,17</a>]. There are rare reports of families with both schwannomatosis and rhabdoid tumor phenotypes [<a href="#rid18">18-20</a>], mostly in families with hypomorphic partially functioning variants [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/5202.html" rel="external">"Uncommon brain tumors", section on 'Atypical teratoid/rhabdoid tumor'</a>.)</p><p><em>SMARCB1 </em>has also been implicated in Coffin-Siris syndrome and a condition causing severe intellectual disability and choroid plexus hyperplasia [<a href="#rid22">22,23</a>]. These conditions are likely caused by germline missense variants acting through a gain-of-function mechanism.</p><p>There are conflicting data about the role of <em>SMARCB1</em> pathogenic variants in patients with multiple meningiomas [<a href="#rid24">24-27</a>]. Somatic variants in <em>SMARCB1</em> have been reported in less than 3 percent of sporadic meningiomas [<a href="#rid28">28-31</a>], but no germline variants were identified in a series of 47 patients with multiple meningiomas [<a href="#rid27">27</a>]. In other reports, pathogenic variants in <em>SMARCB1</em> have been identified in families with schwannomatosis and multiple meningiomas [<a href="#rid24">24-26</a>].</p><p class="headingAnchor" id="H4086003709"><span class="h2"><i>LZTR1 </i>inactivation</span><span class="headingEndMark"> — </span>Pathogenic variants in <em>LZTR1</em> predispose to schwannomatosis in many patients without pathogenic variants in <em>SMARCB1 </em>[<a href="#rid32">32,33</a>]<em>. </em>A study in individuals without <em>SMARCB1</em> or <em>NF2</em> pathogenic variants identified <em>LZTR1</em> pathogenic variants in 6 of 16 patients with familial schwannomatosis (38 percent), 11 of 49 sporadic patients (22 percent), and 2 of 39 patients with unilateral vestibular schwannoma [<a href="#rid33">33</a>].</p><p>As with <em>SMARCB1-</em>related cases, the pattern of genetic alterations suggests a four-hit, three-step model of tumorigenesis in which the altered germline <em>LZTR1</em> gene copy is present in the tumor (hit 1), a segment of chromosome 22 containing the wildtype <em>SMARCB1</em> gene copy and a wildtype copy of the <em>NF2</em> gene is lost (hits 2 and 3), and the remaining wildtype <em>NF2</em> gene copy is altered (hit 4).</p><p><em>LZTR1</em> is located on chromosome 22q11.21, centromeric to both <em>SMARCB1</em> (22q11.23) and <em>NF2</em> (22q12.2). <em>LZTR1</em> has been identified as a tumor suppressor gene and a driver in a subset of glioblastomas [<a href="#rid34">34</a>]. Additionally, somatic <em>LZTR1 </em>pathogenic variants have been found in several other cancers [<a href="#rid35">35</a>] as well as individuals with both dominant and possible recessive Noonan syndrome [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/13558.html" rel="external">"Noonan syndrome"</a>.)</p><p>Consistent with other late-onset tumor predisposition genes, loss-of-function variants in <em>LZTR1</em> are also seen in control populations, suggesting that <em>LZTR1</em> may exhibit reduced or incomplete penetrance [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H3929590886"><span class="h2">Other genetic causes</span><span class="headingEndMark"> — </span>A third gene on chromosome 22q, <em>DGCR8</em>,<em> </em>has been identified in two families with schwannomatosis [<a href="#rid38">38</a>].</p><p>In other cases, loss of heterozygosity (LOH) of chromosome 22q is present, but no pathogenic variants are identified in <em>NF2</em>, <em>SMARCB1</em>, or <em>LZTR1</em>. These cases are referred to as "22q-related schwannomatosis" in the updated diagnostic criteria [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H13669829"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H2842490512"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Most patients with schwannomatosis present in adulthood with one or more symptomatic schwannomas and pain that may or may not localize to known tumors. The average age of symptom onset is 25 to 30 years, and the median age of diagnosis is 40 years [<a href="#rid1">1,6,7,39</a>]. Delays in diagnosis are common.</p><p>Presenting symptoms include the following [<a href="#rid39">39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain</strong> – Pain is reported by over half of patients at the time of presentation. In the majority of patients, pain does not correlate with a specific, identifiable schwannoma. (See <a class="local">'Chronic pain'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palpable mass</strong> – A mass is the presenting symptom in approximately 40 percent of patients. Masses are more often painless than painful.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other symptoms</strong> – Other presenting symptoms vary based on the location of the tumors but can include focal numbness, weakness, and muscle atrophy [<a href="#rid1">1,6,39</a>]. Some patients may be asymptomatic and diagnosed only incidentally based on an imaging study or as a result of a positive family history.</p><p></p><p class="headingAnchor" id="H9167193"><span class="h2">Schwannomas</span><span class="headingEndMark"> — </span>Multiple schwannomas are the hallmark feature of schwannomatosis. Schwannomas are benign tumors of the nerve sheath, typically occurring as solitary, encapsulated masses on cranial nerves, peripheral nerves, or spinal roots. Schwannomas in schwannomatosis can be discrete or plexiform.</p><p class="headingAnchor" id="H1582568850"><span class="h3">Distribution and burden</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral nerves</strong> – Nearly all patients with schwannomatosis have one or more peripheral nerve schwannomas, which are most often located within the arms or legs. Peripheral nerve schwannomas are commonly found in the head and neck region, and can also be seen in the chest, abdomen, and pelvis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cranial nerves</strong> – Nonvestibular cranial nerve schwannomas are reported in up to 10 percent of patients. Unilateral vestibular schwannomas are uncommon but have been reported, primarily in the setting of <em>LZTR1</em> pathogenic variants [<a href="#rid3">3,33,39-41</a>]. Symptoms of cranial nerve schwannomas depend upon the nerve involved. As an example, a trigeminal schwannoma typically presents with pain, numbness, and/or paresthesias in the distribution of one or more branches of the fifth cranial nerve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spinal nerve roots</strong> – Spinal nerve root schwannomas are present in approximately 75 percent of patients, most commonly in the lumbar spine  (<a class="graphic graphic_diagnosticimage graphicRef77534" href="/z/d/graphic/77534.html" rel="external">image 1</a>) [<a href="#rid39">39</a>]. <em>LZTR1</em> pathogenic variants may be associated with an increased incidence of spinal schwannomas [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1">Spinal tumors involve a single area of the spine (ie, cervical, thoracic, or lumbar) in approximately one-half of patients, two areas in one-third, and the entire spine in a small minority. Spinal nerve root schwannomas usually arise from the dorsal sensory roots and present with radicular sensory changes (pain, paresthesias). Radiculopathy with motor manifestations is not common. (See  <a class="medical medical_review" href="/z/d/html/5196.html" rel="external">"Intradural nerve sheath tumors", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subcutaneous nerves</strong> – Subcutaneous schwannomas are seen in 20 to 30 percent of patients, usually fewer than five in number [<a href="#rid43">43</a>]. Subcutaneous schwannomas are palpable or visible masses located <strong>beneath</strong> the skin, and when palpated, the skin moves freely over the mass.</p><p></p><p class="bulletIndent1">This is in contrast with cutaneous or intradermal schwannomas, which are common in <em>NF2</em>-related schwannomatosis (NF2) but are not part of the phenotype of schwannomatosis. Cutaneous schwannomas are located within the skin itself, move with the skin when palpated, and often protrude superficially.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Segmental disease</strong> – Anatomically limited or segmental disease, defined as multiple schwannomas limited to a single limb or two spinal segments, is described in approximately 30 percent of patients [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overall tumor burden</strong> – The overall tumor burden in patients with schwannomatosis has not been well characterized and is difficult to assess clinically, since some tumors may not be visible or palpable on physical examination and may be asymptomatic.</p><p></p><p class="bulletIndent1">In a study of whole-body magnetic resonance imaging (MRI) that included 51 patients with schwannomatosis, 36 patients had one or more internal tumors visualized by MRI [<a href="#rid16">16,43</a>]. The median tumor count in patients with tumors was 4 (range, 1 to 27 tumors), and the median whole-body tumor volume was 39 mL (range, 7 to 1372 mL). Internal tumors were discrete-appearing in 81 percent of patients, plexiform in 8 percent, and both discrete and plexiform in 11 percent.</p><p></p><p class="headingAnchor" id="H3763013059"><span class="h3">Radiographic appearance</span><span class="headingEndMark"> — </span>Radiographically, schwannomas and neurofibromas have a similar appearance and often cannot be distinguished by imaging.</p><p>MRI is the best method for visualizing nerve sheath tumors, which typically have an intermediate signal intensity on T1-weighted images, very high signal intensity on T2-weighted images, and uniform contrast enhancement with a low-intensity rim  (<a class="graphic graphic_diagnosticimage graphicRef58553" href="/z/d/graphic/58553.html" rel="external">image 2</a>) [<a href="#rid44">44</a>]. Nerve sheath tumors are particularly well visualized on short tau inversion recovery (STIR) sequences  (<a class="graphic graphic_diagnosticimage graphicRef89496" href="/z/d/graphic/89496.html" rel="external">image 3</a>). A heterogeneous appearance with cystic degeneration can also be seen and is more typical of schwannoma than neurofibroma.</p><p class="headingAnchor" id="H2126688"><span class="h2">Other tumors</span><span class="headingEndMark"> — </span>Beyond schwannomas, patients with schwannomatosis may be at increased risk for certain other tumors.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meningiomas</strong> – The incidence of meningioma in patients with schwannomatosis was 5 percent in one large series [<a href="#rid39">39</a>]. There have been several documented families with germline <em>SMARCB1</em> pathogenic variants who manifest schwannomatosis as well as multiple meningiomas [<a href="#rid24">24-26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignant peripheral nerve sheath tumors (MPNSTs)</strong> – MPNSTs have been reported in a small number of patients with schwannomatosis [<a href="#rid7">7,19,45,46</a>]. The overall risk of malignant transformation is not well established, however, in part because the pathologic diagnosis of malignant nerve sheath tumors can be challenging. In the largest cohort of patients with schwannomatosis described to date, 3 out of 87 patients (3 percent) were diagnosed with MPNST; upon subsequent neuropathologic review, however, all three tumors were reclassified (two as schwannoma, one as melanoma) [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhabdoid tumors</strong> – Rare families with both multiple schwannomas and rhabdoid tumors, including atypical teratoid/rhabdoid tumors (ATRT) of the central nervous system, in the presence of a germline pathogenic variant in <em>SMARCB1</em> have been reported [<a href="#rid18">18-20</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="headingAnchor" id="H1368954334"><span class="h2">Chronic pain</span><span class="headingEndMark"> — </span>Chronic pain is very common in patients with schwannomatosis, affecting approximately two-thirds of patients [<a href="#rid5">5,7,39</a>]. The etiology of the pain is often complex, with a mix of neuropathic and nociceptive features.</p><p>Risk factors for pain are not well characterized. Tumor size, location, and number do not correlate well with pain-related morbidity [<a href="#rid5">5</a>]. However, total tumor volume correlated with increased pain scores in one study [<a href="#rid42">42</a>]. Additionally, individuals with <em>LZTR1</em> pathogenic variants may have higher pain and worse quality-of-life scores compared with those with <em>SMARCB1</em> pathogenic variants [<a href="#rid42">42</a>].</p><p>Some patients experience pain that does not seem to correlate with specific tumors and may be diffuse in nature. The pain may be difficult to manage medically and can become disabling [<a href="#rid5">5</a>]. (See <a class="local">'Pain management'</a> below.)</p><p class="headingAnchor" id="H13669836"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of schwannomatosis should be considered in a patient presenting with multiple schwannomas, particularly in the presence of an affected family member.</p><p class="headingAnchor" id="H2493061723"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The initial evaluation should include a detailed clinical and family history, review of available tumor pathology, and a high-resolution brain MRI with fine cuts through the internal auditory canal. Family history that could be indicative of schwannomatosis includes the presence of schwannomas, meningiomas, and atypical teratoid/rhabdoid tumors (ATRT). Genetic testing is recommended in the majority of patients with a suspected schwannoma predisposition syndrome [<a href="#rid2">2</a>].</p><p>The most common diagnostic scenario is that of a patient who undergoes biopsy or resection of a nerve sheath tumor that is pathologically confirmed to be a schwannoma, and then additional schwannomas are recognized by clinical history, examination, or imaging in a patient without bilateral vestibular tumors.</p><p class="headingAnchor" id="H9167209"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The diagnosis of schwannomatosis is based on clinical criteria first proposed in 2005, modified in 2006, and revised to include molecular genetic criteria in 2022 [<a href="#rid2">2,5,47</a>]. As of the 2022 criteria, schwannomatosis is further classified according to the available genetic data into one of several diagnoses:</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>SMARCB1</em></strong><strong>-related schwannomatosis</strong> – The diagnosis can be made when an individual meets one of the following criteria:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At least one pathologically confirmed schwannoma or hybrid nerve sheath tumor <strong>and</strong> a <em>SMARCB1</em> pathogenic variant in an unaffected tissue such as blood or saliva</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A common <em>SMARCB1</em> pathogenic variant in two anatomically distinct schwannomas or hybrid nerve sheath tumors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>LZTR1</em></strong><strong>-related schwannomatosis</strong> – The diagnosis can be made when an individual meets one of the following criteria:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At least one pathologically confirmed schwannoma or hybrid nerve sheath tumor <strong>and</strong> an <em>LZTR1</em> pathogenic variant in an unaffected tissue such as blood or saliva</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A common <em>LZTR1</em> pathogenic variant in two anatomically distinct schwannomas or hybrid nerve sheath tumors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>22q-related schwannomatosis</strong> – The diagnosis can be made when an individual meets all of the following criteria:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individual does not meet criteria for <em>NF2</em>-, <em>SMARCB1</em>-, or <em>LTZR1</em>-related schwannomatosis and does not have a germline <em>DGCR8</em> pathogenic variant</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Both of the following molecular features:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Loss of heterozygosity (LOH) of the same chromosome 22q markers in two anatomically distinct schwannomas or hybrid nerve sheath tumors</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A different<em> NF2</em> pathogenic variant in each tumor, which cannot be detected in unaffected tissue</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schwannomatosis not otherwise specified (NOS)</strong> – A diagnosis of schwannomatosis-NOS can be made if both of the following criteria are met and genetic testing was not performed or is not available:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two or more lesions on appropriate imaging consistent with nonintradermal schwannomas</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pathologic confirmation of at least one schwannoma or hybrid nerve sheath tumor</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schwannomatosis not elsewhere classified (NEC)</strong> – A diagnosis of schwannomatosis-NEC can be made if both of the above criteria for schwannomatosis-NOS are met and genetic testing has been performed but does not reveal a pathogenic variant in a known schwannomatosis-related gene.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mosaic schwannomatosis</strong> – Mosaicism for <em>SMARCB1</em>- and <em>LZTR1</em>-related schwannomatosis is confirmed by either of the following in the appropriate clinical context:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At least one pathologically confirmed schwannoma or hybrid nerve sheath tumor <strong>and</strong> clearly less than 50 percent pathogenic variant allele fraction in blood or saliva</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pathogenic variant not detected in blood or saliva <strong>but</strong> a shared pathogenic variant is present in two or more anatomically unrelated tumors</p><p></p><p>It is important to note that there is extensive clinical overlap between mosaic <em>NF2</em>-related schwannomatosis (NF2) and other schwannomatoses, which can lead to misdiagnosis. This underscores the importance of molecular testing in the setting of diagnostic evaluation. (See <a class="local">'Differential diagnosis'</a> below and <a class="local">'Genetic testing'</a> below.)</p><p class="headingAnchor" id="H13669843"><span class="h2">Tumor pathology</span><span class="headingEndMark"> — </span>Pathologic evaluation of a tumor specimen, when available, is essential for the diagnosis of schwannomatosis in order to differentiate schwannomas from other tumors that can arise in the setting of neurofibromatosis (eg, neurofibroma), and increasingly for molecular characterization.</p><p>Schwannomas are benign peripheral nerve sheath tumors composed entirely of neoplastic Schwann cells, arising from cranial nerves, spinal roots, or peripheral nerves. They are typically situated eccentrically to the nerve, displacing the nerve fibers [<a href="#rid10">10</a>]. They may be encapsulated or plexiform in configuration.</p><p>The hallmark pathologic feature is the presence of alternating areas of compact spindle cells arranged in compact fascicles called Antoni A areas, and less cellular and more disorganized areas called Antoni B areas  (<a class="graphic graphic_picture graphicRef51535" href="/z/d/graphic/51535.html" rel="external">picture 1</a>) [<a href="#rid48">48</a>].</p><p>There are no reliable histologic features that distinguish a sporadic (nonsyndromic) schwannoma from a schwannoma related to a schwannomatosis or NF2. However, the presence of abundant myxoid stroma or a hybrid tumor (one with characteristics of both neurofibroma and schwannoma) may be clues to an underlying syndromic diagnosis [<a href="#rid16">16</a>].</p><p>Immunohistochemistry can also help to signal a syndromic diagnosis. Mosaic loss of immunohistochemical expression of <em>SMARCB1</em>/<em>INI1</em> is a reliable marker of schwannomatosis (regardless of the involved gene) and can assist in distinguishing schwannomatosis from an isolated (nonsyndromic) schwannoma. This same mosaic immunohistochemical pattern can be seen in the setting of NF2, and so does not help in distinguishing between schwannomatosis and NF2 [<a href="#rid49">49</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H13669850"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>Patients with suspected schwannomatosis require the following imaging studies to assess extent of disease and exclude alternative diagnoses:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brain MRI with contrast and thin cuts</strong> – High-resolution, contrast-enhanced MRI of the brain with thin cuts (&lt;3 mm with no skipping) through the internal auditory canal should be performed to exclude bilateral eighth nerve tumors, which are <strong>not </strong>compatible with the diagnosis of schwannomatosis and would suggest the alternative diagnosis of NF2. Patients with schwannomatosis can develop unilateral vestibular schwannomas  (<a class="graphic graphic_diagnosticimage graphicRef86508" href="/z/d/graphic/86508.html" rel="external">image 4</a>) or other cranial nerve tumors in the cerebellopontine angle (CPA), although this is relatively uncommon. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whole-spine MRI</strong> – Contrast-enhanced MRI of the entire spine with coronal short tau inversion recovery (STIR) is recommended for all patients at the time of diagnosis to assess the burden of spinal cord involvement and rule out spinal cord impingement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focused tumor MRI</strong> – Focused MRI of known symptomatic masses or of neurologic findings should also be performed. MRI with STIR sequences is especially helpful to visualize nerve sheath tumors  (<a class="graphic graphic_diagnosticimage graphicRef89496" href="/z/d/graphic/89496.html" rel="external">image 3</a>). (See <a class="local">'Radiographic appearance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whole-body MRI </strong>– Where available, whole-body MRI with quantitative apparent diffusion coefficient (ADC) mapping may be useful for delineating extent of disease and tumor characteristics, and for ongoing surveillance of tumors [<a href="#rid50">50</a>].</p><p></p><p class="headingAnchor" id="H238988510"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>For individuals with a known or suspected schwannoma predisposition syndrome, genetic testing is recommended to establish the specific diagnosis, which may have implications for prognosis and family planning. There may be some circumstances in which a clinical diagnosis is sufficient and genetic testing is not necessary. If genetic testing for schwannomatosis is being considered, we recommend referral to a clinical geneticist or genetic counselor who is knowledgeable about the testing protocol and the relevant issues for discussion with patients and their families. (See <a class="local">'Counseling and prognosis'</a> below and  <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p>Aside from <em>SMARCB1</em> and <em>LZTR1</em>, there are likely other causative genes and molecular regulatory mechanisms in schwannomatosis that have not yet been identified, which limits the ability of genetic testing to exclude the diagnosis of schwannomatosis [<a href="#rid51">51</a>]. Additionally, genetic testing for schwannomatosis is not yet helpful in determining prognosis or informing medical management.</p><p>The decision to pursue genetic testing for <em>SMARCB1</em> and/or <em>LZTR1</em> is individualized and depends on a variety of factors, including the age and reproductive status of the patient, the presence or absence of additional family members who might be at risk, the cost of the test and insurance coverage, whether there are other affected family members, and preferences with regard to reproductive decision-making.</p><p>The protocol for genetic testing in the setting of schwannomatosis can also be complex and depends on both the individual and family history  (<a class="graphic graphic_algorithm graphicRef132704" href="/z/d/graphic/132704.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef130604" href="/z/d/graphic/130604.html" rel="external">algorithm 2</a>). Clinicians must select the appropriate tissue to submit for testing; coordinate testing for the <em>NF2</em>, <em>SMARCB1</em>, and <em>LZTR1</em> genes; and interpret results accurately [<a href="#rid52">52</a>]. In addition to deoxyribonucleic acid (DNA) testing, ribonucleic acid (RNA) testing should be considered to evaluate for a deep intronic <em>SMARCB1 </em>variant in patients with suspected schwannomatosis who have negative testing for <em>NF2</em>, <em>SMARB1</em>, and <em>LZTR1 </em>[<a href="#rid53">53</a>].</p><p>Of note, some individuals have been identified who carry a variant in <em>NF2</em>, <em>SMARCB1</em>, or <em>LZTR1 </em>in blood but do not have clinical features of a schwannomatosis predisposition syndrome (eg, in an asymptomatic individual who underwent genetic sequencing for another indication). Given the incomplete penetrance of <em>SMARCB1</em> and <em>LZTR1</em> pathogenic variants, such an incidental finding cannot be used as a standalone criterion to diagnose schwannomatosis [<a href="#rid2">2</a>]. Such individuals and their at-risk relatives should be referred to a tertiary care center with expertise in schwannomatosis for further evaluation and genetic counseling.</p><p class="headingAnchor" id="H9167216"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Multiple schwannomas can also be seen in association with <em>NF2</em>-related schwannomatosis (NF2). In particular, there is extensive clinical overlap between mosaic NF2 and other schwannomatoses.</p><p>Differentiating schwannomatosis from NF2 can be challenging but is critical, as management decisions and counseling are very different for the two disorders. Whenever possible, patients in whom any of these diagnoses are being considered should be referred to a multidisciplinary team with experience in the diagnosis and management of neurofibromatosis.</p><p>The cardinal feature that distinguishes NF2 from schwannomatosis is the presence of bilateral vestibular schwannomas, which are a key clinical feature of NF2 and incompatible with a diagnosis of schwannomatosis. The absence of bilateral vestibular schwannomas on high-resolution brain MRI is particularly reliable for ruling out NF2 in patients over the age of 30 years. Patients younger than 30 years with a unilateral vestibular schwannoma may still go on to develop a contralateral tumor. The clinical criteria for the diagnosis of NF2 are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5206.html" rel="external">"<i>NF2</i>-related schwannomatosis (formerly neurofibromatosis type 2)", section on 'Diagnostic criteria'</a>.)</p><p>Differentiating schwannomatosis from NF2 can be difficult, and molecular testing may be helpful to reach a definitive diagnosis in these circumstances (see <a class="local">'Genetic testing'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mosaic NF2</strong> – Individuals who have a mosaic form of NF2 (approximately 30 percent of all people with NF2) can present with multiple schwannomas and no vestibular schwannomas, thereby mimicking the presentation of schwannomatosis [<a href="#rid54">54</a>]. In one study, mosaic NF2 misdiagnosed as schwannomatosis accounted for at least 9 percent of clinically diagnosed schwannomatosis cases [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unilateral vestibular schwannoma</strong> – Individuals with schwannomatosis can develop unilateral vestibular schwannomas, thereby mimicking the presentation of NF2 [<a href="#rid33">33,40,41</a>]. One study found that 1 to 2 percent of individuals with schwannomatosis were misdiagnosed with mosaic NF2 [<a href="#rid3">3</a>]. This phenotype is most common with <em>LRTZ1</em>-related schwannomatosis [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meningiomas</strong> – Multiple meningiomas are common in NF2 and have been described in some individuals with schwannomatosis, making it difficult to distinguish between schwannomatosis and NF2 based on the presence or absence of meningiomas.</p><p></p><p class="bulletIndent1">A detailed family history, probing for the presence of symptoms consistent with either schwannomatosis or NF2, is imperative. Schwannomas and meningiomas can be seen in families with either syndrome. In the setting of NF2, however, there may be an additional family history of vestibular schwannomas, hearing loss, tinnitus, or ependymomas, which would be unlikely to occur within a schwannomatosis pedigree. (See  <a class="medical medical_review" href="/z/d/html/5206.html" rel="external">"<i>NF2</i>-related schwannomatosis (formerly neurofibromatosis type 2)", section on 'Clinical features'</a>.)</p><p></p><p>Aside from NF2, segmental or spinal forms of neurofibromatosis type 1 (NF1) may occasionally be considered in the initial differential diagnosis but are typically ruled out by other clinical findings (such as cutaneous features of NF1) or by pathologic diagnosis of a neurofibroma as opposed to a schwannoma. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H13669864"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of patients with schwannomatosis is primarily symptomatic. There are no established medical therapies that target the underlying disease at the present time. Whenever possible, patients should be cared for by a multidisciplinary team with expertise in the care of patients with schwannoma predisposition syndromes.</p><p class="headingAnchor" id="H13669878"><span class="h2">Pain management</span><span class="headingEndMark"> — </span>Pain is one of the most common symptoms of schwannomatosis. Severity of pain varies widely between patients and can often be severe and incapacitating. Pain can be localized or diffuse and often does not correlate well with the location of known schwannomas.</p><p>Early involvement of a multidisciplinary pain team should be considered. As a last resort, surgical resection of painful schwannomas may be considered if pain is not satisfactorily controlled by other means. (See <a class="local">'Surgery'</a> below.)</p><p class="headingAnchor" id="H13669885"><span class="h3">Pharmacologic therapy</span><span class="headingEndMark"> — </span>Painful schwannomas have a significant neuropathic component. In our experience, treatment with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> and use of short-acting opioids and/or nonsteroidal anti-inflammatories for breakthrough pain can be successful for many patients.</p><p>Additional agents, including tricyclic antidepressants such as <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>, serotonin-norepinephrine reuptake inhibitors such as <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>, cannabinoids, or antiepileptics such as <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, may be used as adjuncts or independently. (See  <a class="medical medical_review" href="/z/d/html/126633.html" rel="external">"Pharmacologic management of chronic non-cancer pain in adults", section on 'General principles of drug selection'</a> and  <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain"</a>.)</p><p class="headingAnchor" id="H13669892"><span class="h3">Nonpharmacologic therapy</span><span class="headingEndMark"> — </span>There are a variety of nonpharmacologic options to treat pain that may be effective, although no clinical trials have examined such modalities specifically for schwannomatosis.</p><p>In our experience, patients may benefit from meditation, yoga, and mindfulness-based stress reduction (MBSR) techniques to help with relaxation, stress reduction, dealing with difficult emotions, examining thoughts and beliefs about pain, and training the mind to be less reactive to painful sensations [<a href="#rid55">55-59</a>]. Biofeedback and hypnosis can assist with managing the anxiety that often accompanies pain and train the brain to be less reactive to pain [<a href="#rid60">60-62</a>]. Many patients have used acupuncture, and in several clinical trials acupuncture has shown promise in alleviating chronic and neuropathic pain [<a href="#rid63">63,64</a>]. (See  <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults"</a>.)</p><p class="headingAnchor" id="H13669899"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>When surgery is necessary, indications include medically refractory local pain, spinal cord compression, or impingement of other organs. Surgical resection of these tumors is often complex and may put patients at risk of additional neurologic compromise.</p><p>Surgical therapy for schwannomatosis is highly individualized and depends on the size, location, and complexity of tumors; the need for pathologic conformation for diagnosis; the presence and/or progression of neurologic or systemic symptoms; and pain.</p><p>The goals of surgery should be explicitly discussed with the patient. In general, the goal of surgery is to prevent progression of symptoms, as neurologic dysfunction is unlikely to be reversed by tumor resection. If pain is the primary indication, patients should be counseled that, though surgery may relieve pain, it is also possible that it will be ineffective or could even worsen pain and dysfunction.</p><p class="headingAnchor" id="H13669906"><span class="h1">SURVEILLANCE</span><span class="headingEndMark"> — </span>The optimal type and frequency of surveillance imaging has not been established in schwannomatosis. We suggest the following approach, which is closely aligned with that of a European clinical practice guideline for patients with schwannomatosis [<a href="#rid53">53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>MRI is the preferred imaging modality for schwannoma surveillance. We find that MRI with and without gadolinium and multiplanar short tau inversion recovery (STIR) imaging provides the most useful information. Some centers use ultrasound for monitoring superficial tumors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do not find positron emission tomography (PET) useful for monitoring schwannomas as it is not a reliable predictor of malignant conversion [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For asymptomatic, molecularly confirmed individuals with a relative with schwannomas, we recommend screening imaging of whole spine and brain/internal auditory canal (IAC) with and without gadolinium at the time of diagnosis or at an age at which the patient can undergo MRI without the need for anesthesia (typically age 12 and older). If initial screening imaging is negative, our practice is to repeat imaging every five years or sooner if symptoms develop. Others have suggested performing brain and spine MRI every two to three years in all patients, starting at age 10 for those with <em>SMARCB1</em> pathogenic variants and age 15 to 19 for those with <em>LZTR1</em> pathogenic variants [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with symptomatic tumors, the frequency of MRI is dependent on the severity of symptoms, tumor location, and clinical evidence of progression. For patients with intradural spinal schwannomas and/or cranial nerve schwannomas, we typically image on an annual basis at minimum. For many patients with tumors in multiple body regions, we use whole-body MRI at the time of diagnosis to establish the location of tumors and then serially for monitoring. A changing tumor, especially one causing functional impairment in a patient with <em>SMARCB1</em>-related schwannomatosis, requires prompt evaluation with focused tumor contrast-enhanced MRI to look for signs of malignant transformation [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with known but asymptomatic schwannomas, surveillance with serial imaging is not necessary unless they are considered to be high risk for future neurologic compromise, such as those with intradural spinal schwannomas causing spinal cord compression or intracranial schwannomas.</p><p></p><p class="headingAnchor" id="H723040"><span class="h1">COUNSELING AND PROGNOSIS</span><span class="headingEndMark"> — </span>Individuals with schwannomatosis are at risk of having other affected family members, including children.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission risk</strong> – For individuals with a known germline <em>SMARCB1</em> or <em>LZTR1</em> pathogenic variant, the transmission risk to offspring is 50 percent. For individuals with no known <em>SMARCB1</em> or <em>LZTR1 </em>pathogenic variant who have an affected parent, the transmission risk is also considered to be 50 percent.</p><p></p><p class="bulletIndent1">For individuals with no affected parent and no known pathogenic variant (ie, sporadic schwannomatosis), estimating the transmission risk is more complicated. Many of these patients will be mosaic for a de novo variant, and if the variant is also present in the germline, there may be an appreciable (but hard to quantify) transmission risk (0 to 50 percent). An additional source of uncertainty is that schwannomatosis is probably not fully penetrant, meaning that individuals can carry a pathogenic variant that causes schwannomatosis but never develop the condition. Rates of nonpenetrance and mosaicism are not yet well characterized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sharing the diagnosis with family members</strong> – Patients diagnosed with schwannomatosis are counseled to consider sharing the diagnosis with family members, particularly those who have symptoms consistent with the condition. Asymptomatic family members can be screened with whole-body MRI or genetic testing (if a pathogenic variant has been identified within the family) but should first be counseled about issues regarding presymptomatic testing and the possible impact on insurability (health and life) based on the results of screening. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing", section on 'Ethical, legal, and psychosocial issues'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history</strong> – The natural history of schwannomatosis is not well documented, and the phenotypic spectrum remains to be fully characterized. It appears that patients with schwannomatosis do <strong>not</strong> have a decreased lifespan, which is in marked contrast to patients with <em>NF2</em>-related schwannomatosis (NF2) [<a href="#rid3">3,5</a>]. However, more data are needed to understand the risk of malignant peripheral nerve sheath tumors (MPNSTs) and other malignancies in patients with schwannomatosis, especially those related to <em>SMARCB1 </em>[<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">An <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fsid2011.squarespace.com%2F&amp;token=y4UfLjKM7qyuzKYcoQtwa6ZO5FtQ2koNl7Ag1fKytBZ37CBSYrxV0ZTqBqfTc34j&amp;TOPIC_ID=16350" target="_blank">international database</a> has been established to facilitate progress in understanding the natural history of schwannomatosis. Another resource for patients and families with schwannomatosis is the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ctf.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEX%2ByQ%2FSsqWqNANGkzTP5RAQ%3D&amp;TOPIC_ID=16350" target="_blank">Children's Tumor Foundation</a>.</p><p></p><p class="headingAnchor" id="H9167224"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>What is schwannomatosis?</strong> – Schwannomatosis is the name originally coined for a neurocutaneous syndrome that is genetically distinct from neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2), in which patients develop multiple noncutaneous nerve sheath tumors, called schwannomas, in the absence of bilateral vestibular schwannomas.</p><p></p><p class="bulletIndent1">In 2022, the nomenclature was updated to recognize NF2 (now called <em>NF2</em>-related schwannomatosis) and schwannomatosis as part of a spectrum of schwannoma predisposition syndromes with extensive clinical overlap, defined in many cases by pathogenic variants in one of several genes on chromosome 22. This topic will continue to use the term "schwannomatosis" to refer to the non-<em>NF2</em>-related schwannomatoses for brevity and consistency, unless otherwise noted. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Schwannomatosis is familial in approximately 20 percent of cases and sporadic in the remaining. Germline pathogenic variants in either <em>SMARCB1</em> or <em>LZTR1</em> are responsible for a majority of familial cases and up to 40 percent of sporadic cases. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Most patients present in their 20s or 30s with a symptomatic nerve sheath tumor and localized pain that may or may not be associated with a discrete mass. The median age of diagnosis is 40 years. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor distribution</strong> – Schwannomas can form along the course of any peripheral nerve. The most common locations are the extremities and spinal roots; tumors can also be seen intracranially (along cranial nerves) and in the trunk (along peripheral nerves in the chest, abdomen, or pelvis). (See <a class="local">'Schwannomas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of schwannomatosis is based on characteristic clinical and genetic findings, family history, and exclusion of a diagnosis of NF2. Patients require high-resolution brain MRI, spine MRI, and genetic testing in selected cases  (<a class="graphic graphic_algorithm graphicRef132704" href="/z/d/graphic/132704.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef130604" href="/z/d/graphic/130604.html" rel="external">algorithm 2</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The most important alternative diagnosis to consider in patients with multiple schwannomas is NF2. The distinction can be challenging in many patients but carries important implications for management and prognosis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Referral </strong>– Patients in whom the diagnosis is being considered should be referred to a multidisciplinary team with experience in the diagnosis and management of neurofibromatosis and schwannomatosis, whenever possible. (See <a class="local">'Counseling and prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Management of patients with schwannomatosis is primarily symptomatic, focusing on chronic pain management in many patients. Indications for surgical resection of schwannomas include refractory local pain, spinal cord compression, or impingement of other organs. (See <a class="local">'Pain management'</a> above and <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance </strong>– Where available, whole-body MRI is preferred for monitoring of multiple schwannomas. For patients with symptomatic tumors or tumors in critical locations (eg, spinal cord), we obtain imaging yearly for surveillance. (See <a class="local">'Surveillance'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">MacCollin M, Woodfin W, Kronn D, Short MP. Schwannomatosis: a clinical and pathologic study. Neurology 1996; 46:1072.</a></li><li><a class="nounderline abstract_t">Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genet Med 2022; 24:1967.</a></li><li><a class="nounderline abstract_t">Evans DG, Bowers NL, Tobi S, et al. Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry 2018; 89:1215.</a></li><li><a class="nounderline abstract_t">Antinheimo J, Sankila R, Carpén O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 2000; 54:71.</a></li><li><a class="nounderline abstract_t">MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology 2005; 64:1838.</a></li><li><a class="nounderline abstract_t">Jacoby LB, MacCollin M, Parry DM, et al. Allelic expression of the NF2 gene in neurofibromatosis 2 and schwannomatosis. Neurogenetics 1999; 2:101.</a></li><li><a class="nounderline abstract_t">Gonzalvo A, Fowler A, Cook RJ, et al. Schwannomatosis, sporadic schwannomatosis, and familial schwannomatosis: a surgical series with long-term follow-up. Clinical article. J Neurosurg 2011; 114:756.</a></li><li><a class="nounderline abstract_t">Seppälä MT, Sainio MA, Haltia MJ, et al. Multiple schwannomas: schwannomatosis or neurofibromatosis type 2? J Neurosurg 1998; 89:36.</a></li><li><a class="nounderline abstract_t">Hulsebos TJ, Kenter SB, Jakobs ME, et al. SMARCB1/INI1 maternal germ line mosaicism in schwannomatosis. Clin Genet 2010; 77:86.</a></li><li><a class="nounderline abstract_t">Hadfield KD, Newman WG, Bowers NL, et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet 2008; 45:332.</a></li><li><a class="nounderline abstract_t">Boyd C, Smith MJ, Kluwe L, et al. Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet 2008; 74:358.</a></li><li><a class="nounderline abstract_t">Sestini R, Bacci C, Provenzano A, et al. Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. Hum Mutat 2008; 29:227.</a></li><li><a class="nounderline abstract_t">Rousseau G, Noguchi T, Bourdon V, et al. SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis. BMC Neurol 2011; 11:9.</a></li><li><a class="nounderline abstract_t">Smith MJ, Wallace AJ, Bowers NL, et al. Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis. Neurogenetics 2012; 13:141.</a></li><li><a class="nounderline abstract_t">Hadfield KD, Smith MJ, Urquhart JE, et al. Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 2010; 29:6216.</a></li><li><a class="nounderline abstract_t">Plotkin SR, Blakeley JO, Evans DG, et al. Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A 2013; 161A:405.</a></li><li><a class="nounderline abstract_t">Versteege I, Sévenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998; 394:203.</a></li><li><a class="nounderline abstract_t">Swensen JJ, Keyser J, Coffin CM, et al. Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1. J Med Genet 2009; 46:68.</a></li><li><a class="nounderline abstract_t">Carter JM, O'Hara C, Dundas G, et al. Epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with "neuroblastoma-like" schwannomatosis and a novel germline SMARCB1 mutation. Am J Surg Pathol 2012; 36:154.</a></li><li><a class="nounderline abstract_t">Eaton KW, Tooke LS, Wainwright LM, et al. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 2011; 56:7.</a></li><li><a class="nounderline abstract_t">Smith MJ, Wallace AJ, Bowers NL, et al. SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors. Cancer Genet 2014; 207:373.</a></li><li><a class="nounderline abstract_t">Agaimy A, Foulkes WD. Hereditary SWI/SNF complex deficiency syndromes. Semin Diagn Pathol 2018; 35:193.</a></li><li><a class="nounderline abstract_t">Diets IJ, Prescott T, Champaigne NL, et al. A recurrent de novo missense pathogenic variant in SMARCB1 causes severe intellectual disability and choroid plexus hyperplasia with resultant hydrocephalus. Genet Med 2019; 21:572.</a></li><li><a class="nounderline abstract_t">van den Munckhof P, Christiaans I, Kenter SB, et al. Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. Neurogenetics 2012; 13:1.</a></li><li><a class="nounderline abstract_t">Bacci C, Sestini R, Provenzano A, et al. Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics 2010; 11:73.</a></li><li><a class="nounderline abstract_t">Christiaans I, Kenter SB, Brink HC, et al. Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. J Med Genet 2011; 48:93.</a></li><li><a class="nounderline abstract_t">Hadfield KD, Smith MJ, Trump D, et al. SMARCB1 mutations are not a common cause of multiple meningiomas. J Med Genet 2010; 47:567.</a></li><li><a class="nounderline abstract_t">Schmitz U, Mueller W, Weber M, et al. INI1 mutations in meningiomas at a potential hotspot in exon 9. Br J Cancer 2001; 84:199.</a></li><li><a class="nounderline abstract_t">Rieske P, Zakrzewska M, Piaskowski S, et al. Molecular heterogeneity of meningioma with INI1 mutation. Mol Pathol 2003; 56:299.</a></li><li><a class="nounderline abstract_t">Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013; 339:1077.</a></li><li><a class="nounderline abstract_t">Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013; 45:285.</a></li><li><a class="nounderline abstract_t">Piotrowski A, Xie J, Liu YF, et al. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet 2014; 46:182.</a></li><li><a class="nounderline abstract_t">Smith MJ, Isidor B, Beetz C, et al. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology 2015; 84:141.</a></li><li><a class="nounderline abstract_t">Frattini V, Trifonov V, Chan JM, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013; 45:1141.</a></li><li><a class="nounderline abstract_t">Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39:D945.</a></li><li><a class="nounderline abstract_t">Johnston JJ, van der Smagt JJ, Rosenfeld JA, et al. Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants. Genet Med 2018; 20:1175.</a></li><li><a class="nounderline abstract_t">Pagnamenta AT, Kaisaki PJ, Bennett F, et al. Delineation of dominant and recessive forms of LZTR1-associated Noonan syndrome. Clin Genet 2019; 95:693.</a></li><li><a class="nounderline abstract_t">Nogué C, Chong AS, Grau E, et al. DGCR8 and the six hit, three-step model of schwannomatosis. Acta Neuropathol 2022; 143:115.</a></li><li><a class="nounderline abstract_t">Merker VL, Esparza S, Smith MJ, et al. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist 2012; 17:1317.</a></li><li><a class="nounderline abstract_t">Smith MJ, Kulkarni A, Rustad C, et al. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis. Am J Med Genet A 2012; 158A:215.</a></li><li><a class="nounderline abstract_t">Smith MJ, Bowers NL, Bulman M, et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology 2017; 88:87.</a></li><li><a class="nounderline abstract_t">Jordan JT, Smith MJ, Walker JA, et al. Pain correlates with germline mutation in schwannomatosis. Medicine (Baltimore) 2018; 97:e9717.</a></li><li><a class="nounderline abstract_t">Plotkin SR, Bredella MA, Cai W, et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One 2012; 7:e35711.</a></li><li><a class="nounderline abstract_t">Pilavaki M, Chourmouzi D, Kiziridou A, et al. Imaging of peripheral nerve sheath tumors with pathologic correlation: pictorial review. Eur J Radiol 2004; 52:229.</a></li><li><a class="nounderline abstract_t">Evans DG, Huson SM, Birch JM. Malignant peripheral nerve sheath tumours in inherited disease. Clin Sarcoma Res 2012; 2:17.</a></li><li><a class="nounderline abstract_t">Eelloo JA, Smith MJ, Bowers NL, et al. Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant. Fam Cancer 2019; 18:445.</a></li><li><a class="nounderline abstract_t">Baser ME, Friedman JM, Evans DG. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology 2006; 66:730.</a></li><li class="breakAll">Pathology and genetics of tumours of the nervous system. In: World Health Organization Classification of Tumours of the Nervous System, Editorial and Consensus Conference Working Group, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC Press, Lyon, France 2007.</li><li><a class="nounderline abstract_t">Caltabiano R, Magro G, Polizzi A, et al. A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas. Childs Nerv Syst 2017; 33:933.</a></li><li><a class="nounderline abstract_t">Ahlawat S, Blakeley JO, Langmead S, et al. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Skeletal Radiol 2020; 49:199.</a></li><li><a class="nounderline abstract_t">Louvrier C, Pasmant E, Briand-Suleau A, et al. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Neuro Oncol 2018; 20:917.</a></li><li><a class="nounderline abstract_t">Radtke HB, Bergner AL, Goetsch AL, et al. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors. J Genet Couns 2020; 29:692.</a></li><li><a class="nounderline abstract_t">Evans DG, Mostaccioli S, Pang D, et al. ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis. Eur J Hum Genet 2022; 30:812.</a></li><li><a class="nounderline abstract_t">Kehrer-Sawatzki H, Kluwe L, Friedrich RE, et al. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas. Hum Genet 2018; 137:543.</a></li><li><a class="nounderline abstract_t">Rosenzweig S, Greeson JM, Reibel DK, et al. Mindfulness-based stress reduction for chronic pain conditions: variation in treatment outcomes and role of home meditation practice. J Psychosom Res 2010; 68:29.</a></li><li><a class="nounderline abstract_t">Ussher M, Spatz A, Copland C, et al. Immediate effects of a brief mindfulness-based body scan on patients with chronic pain. J Behav Med 2014; 37:127.</a></li><li><a class="nounderline abstract_t">Marchand WR. Mindfulness-based stress reduction, mindfulness-based cognitive therapy, and Zen meditation for depression, anxiety, pain, and psychological distress. J Psychiatr Pract 2012; 18:233.</a></li><li><a class="nounderline abstract_t">Michalsen A, Traitteur H, Lüdtke R, et al. Yoga for chronic neck pain: a pilot randomized controlled clinical trial. J Pain 2012; 13:1122.</a></li><li><a class="nounderline abstract_t">Ward L, Stebbings S, Cherkin D, Baxter GD. Yoga for functional ability, pain and psychosocial outcomes in musculoskeletal conditions: a systematic review and meta-analysis. Musculoskeletal Care 2013; 11:203.</a></li><li><a class="nounderline abstract_t">Tomé-Pires C, Miró J. Hypnosis for the management of chronic and cancer procedure-related pain in children. Int J Clin Exp Hypn 2012; 60:432.</a></li><li><a class="nounderline abstract_t">Jensen MP, Barber J, Romano JM, et al. Effects of self-hypnosis training and EMG biofeedback relaxation training on chronic pain in persons with spinal-cord injury. Int J Clin Exp Hypn 2009; 57:239.</a></li><li><a class="nounderline abstract_t">Abdeshahi SK, Hashemipour MA, Mesgarzadeh V, et al. Effect of hypnosis on induction of local anaesthesia, pain perception, control of haemorrhage and anxiety during extraction of third molars: a case-control study. J Craniomaxillofac Surg 2013; 41:310.</a></li><li><a class="nounderline abstract_t">Carlsson CP, Sjölund BH. Acupuncture for chronic low back pain: a randomized placebo-controlled study with long-term follow-up. Clin J Pain 2001; 17:296.</a></li><li><a class="nounderline abstract_t">Norrbrink C, Lundeberg T. Acupuncture and massage therapy for neuropathic pain following spinal cord injury: an exploratory study. Acupunct Med 2011; 29:108.</a></li><li><a class="nounderline abstract_t">Lieber B, Han B, Allen J, et al. Utility of positron emission tomography in schwannomatosis. J Clin Neurosci 2016; 30:138.</a></li><li><a class="nounderline abstract_t">Evans DGR, Salvador H, Chang VY, et al. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders. Clin Cancer Res 2017; 23:e54.</a></li></ol></div><div id="topicVersionRevision">Topic 16350 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8780094" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Schwannomatosis: a clinical and pathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35674741" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29909380" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Schwannomatosis: a genetic and epidemiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10636128" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955931" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diagnostic criteria for schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369886" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Allelic expression of the NF2 gene in neurofibromatosis 2 and schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20932094" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Schwannomatosis, sporadic schwannomatosis, and familial schwannomatosis: a surgical series with long-term follow-up. Clinical article.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9647170" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Multiple schwannomas: schwannomatosis or neurofibromatosis type 2?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19912265" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : SMARCB1/INI1 maternal germ line mosaicism in schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285426" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18647326" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18072270" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21255467" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22434358" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20729918" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23401320" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9671307" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19124645" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082606" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with "neuroblastoma-like" schwannomatosis and a novel germline SMARCB1 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21108436" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24933152" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29397238" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hereditary SWI/SNF complex deficiency syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29907796" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A recurrent de novo missense pathogenic variant in SMARCB1 causes severe intellectual disability and choroid plexus hyperplasia with resultant hydrocephalus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22038540" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19582488" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20930055" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472658" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : SMARCB1 mutations are not a common cause of multiple meningiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11161377" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : INI1 mutations in meningiomas at a potential hotspot in exon 9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514925" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Molecular heterogeneity of meningioma with INI1 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23348505" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23334667" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24362817" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25480913" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23917401" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The integrated landscape of driver genomic alterations in glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20952405" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29469822" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30859559" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Delineation of dominant and recessive forms of LZTR1-associated Noonan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34821987" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : DGCR8 and the six hit, three-step model of schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22927469" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical features of schwannomatosis: a retrospective analysis of 87 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22105938" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27856782" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29384852" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pain correlates with germline mutation in schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22558206" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15544900" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Imaging of peripheral nerve sheath tumors with pathologic correlation: pictorial review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23036231" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Malignant peripheral nerve sheath tumours in inherited disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31240424" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534111" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Increasing the specificity of diagnostic criteria for schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534111" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Increasing the specificity of diagnostic criteria for schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28365909" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31396668" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29409008" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32602153" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35361920" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30006736" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20004298" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mindfulness-based stress reduction for chronic pain conditions: variation in treatment outcomes and role of home meditation practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23129105" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Immediate effects of a brief mindfulness-based body scan on patients with chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22805898" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mindfulness-based stress reduction, mindfulness-based cognitive therapy, and Zen meditation for depression, anxiety, pain, and psychological distress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23117107" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Yoga for chronic neck pain: a pilot randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23300142" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Yoga for functional ability, pain and psychosocial outcomes in musculoskeletal conditions: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22917107" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hypnosis for the management of chronic and cancer procedure-related pain in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19459087" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effects of self-hypnosis training and EMG biofeedback relaxation training on chronic pain in persons with spinal-cord injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23253486" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of hypnosis on induction of local anaesthesia, pain perception, control of haemorrhage and anxiety during extraction of third molars: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11783809" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Acupuncture for chronic low back pain: a randomized placebo-controlled study with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21474490" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Acupuncture and massage therapy for neuropathic pain following spinal cord injury: an exploratory study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26960263" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Utility of positron emission tomography in schwannomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28620005" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
